Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Gastric Cancer Clinical Trials

52 recruiting trials for Gastric Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
52
Total Trials
52
Recruiting Now
3
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1 / Phase 2NCT06047379

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the...

Sponsor: Neonc Technologies, Inc.Enrolling: 1346 locations
RECRUITINGNCT05349227

Comprehensive Outcomes for After Cancer Health

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary...

Sponsor: Pack HealthEnrolling: 6257 locations
RECRUITINGPhase 1 / Phase 2NCT03190941

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of...

Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This...

Sponsor: National Cancer Institute (NCI)Enrolling: 1101 location
RECRUITINGPhase 2NCT03935893

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in...

Sponsor: Udai KammulaEnrolling: 2401 location
RECRUITINGPhase 1NCT05277766

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal...

Sponsor: University Hospital, GhentEnrolling: 451 location
RECRUITINGPhase 1NCT06500052

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal...

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 201 location
RECRUITINGPhase 2 / Phase 3NCT06782412

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast...

The aim of the project is to demonstrate superior detection ratio of \[18F\]AlF-FAPI-74 PET/CT compared to \[18F\]FDG PET/CT or conventional imaging in treatment-naïve, newly...

Sponsor: KU LeuvenEnrolling: 1093 locations
RECRUITINGPhase 1NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks...

Sponsor: Baylor College of MedicineEnrolling: 451 location
RECRUITINGPhase 2NCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer...

Sponsor: AstraZenecaEnrolling: 22420 locations
RECRUITINGNCT06904365

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of...

Sponsor: Washington University School of MedicineEnrolling: 101 location
RECRUITINGNCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal...

Sponsor: University of NebraskaEnrolling: 99999920 locations
RECRUITINGPhase 1 / Phase 2NCT06239194

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

Sponsor: ModeX Therapeutics, An OPKO Health CompanyEnrolling: 1156 locations
RECRUITINGNCT07076979

Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric...

This prospective clinical observational study aims to construct a metabolite database specifically for gastric cancer patients using metabolomics technology. It seeks to develop...

Sponsor: Shanghai Minimally Invasive Surgery CenterEnrolling: 2501 location
RECRUITINGNCT06982768

How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer

DNA methylation is one of the key mechanisms that are thought to underlie the association between aging and cancer. Several methylation-based measures of biological aging have...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 2451 location
RECRUITINGNCT07056010

Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion...

This is a prospective, open-label, single-center, Phase II clinical trial. Thirty patients with HER2-negative gastric adenocarcinoma or gastroesophageal junction (GEJ) cancer,...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 301 location
RECRUITINGPhase 3NCT04787354

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX...

Sponsor: Hallym University Medical CenterEnrolling: 9761 location
RECRUITINGNCT06735105

Study on the Value of Three DWI Scanning Sequences in Staging of Gastric Cancer

Accurate staging is critical for effective gastric cancer treatment planning. Conventional DWI (C-DWI) has limitations in image quality due to magnetic field inhomogeneity, which...

Sponsor: Yunnan Cancer HospitalEnrolling: 1291 location
RECRUITINGPhase 2NCT07194005

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced...

Sponsor: Fudan UniversityEnrolling: 301 location
RECRUITINGNCT06639490

Efficacy of RUS GA Surgical Navigation for Robot-assisted Distal Gastrectomy in Gastric Cancer Patients

This investigator-initiated, randomized superiority clinical trial aims to demonstrate the clinical effectiveness of RUS GA Surgical Navigation, an endoscopic imaging treatment...

Sponsor: Yonsei UniversityEnrolling: 3301 location
RECRUITINGNCT05344339

Billroth-II Modified Versus Roux-en-Y After Distal Gastrectomy for Gastric Cancer

There are Billroth-I, Billroth-II, Billroth-II with Braun, and Roux-en-Y reconstruction after distal gastrectomy. Hypothesis: Billroth-II modified method is non-inferior to...

Sponsor: University Medical Center Ho Chi Minh City (UMC)Enrolling: 3201 location
RECRUITINGNCT05537129

Laparoscopic vs Open Total Gastrectomy for Gastric Cancer

The aim of the present study is to demonstrated the the safety and feasibility of laparoscopic total gastrectomy comparing with open total gastrectomy.

Sponsor: Fudan UniversityEnrolling: 6001 location
RECRUITINGPhase 2NCT05494060

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric...

This is an open label, randomized, phase Ⅱ, multi-cohort study to treat subjects with ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma. The patients will be...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 801 location
RECRUITINGPhase 3NCT06755554

Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer

The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of...

Sponsor: Ukrainian Society of Clinical OncologyEnrolling: 1052 locations
RECRUITINGNCT06417892

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

To explore the efficacy and safety of fruquintinib and albumin-paclitaxel combined with or without PD-1 antibody in the second-line treatment of advanced gastric/gastroesophageal...

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesEnrolling: 601 location
RECRUITINGNCT07069842

The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating...

Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved. The emergence of immunotherapy has broken...

Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical CollegeEnrolling: 1701 location
RECRUITINGNCT06308510

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish...

Sponsor: Erasmus Medical CenterEnrolling: 631 location
RECRUITINGPhase 2NCT06157996

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low...

This is a multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of intensive treatment with lenvatinib plus tislelizumab and CapeOX as first-line...

Sponsor: Nanfang Hospital, Southern Medical UniversityEnrolling: 921 location
RECRUITINGNCT02139605

"Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy

Stomach cancer is the second most common cause of cancer-related deaths in India. Curative surgery offers the only chance of improving survival in this cancer. In patients whose...

Sponsor: Tata Memorial CentreEnrolling: 4001 location
RECRUITINGNCT03250091

Surveillance of Patients With Precancerous Lesions of the Stomach

The project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals....

Sponsor: University of LatviaEnrolling: 20001 location
RECRUITINGNCT05514769

Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer

This research is designed to compare proximal gastrectomy anterior anastomosis with pyloroplasty with esophagogastric anastomosis for gastric cancer. Gastroesophageal reflux...

Sponsor: Nanchong Central HospitalEnrolling: 601 location
RECRUITINGPhase 3NCT01917552

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

multi-center, prospective, randomized, open-label phase III

Sponsor: Asan Medical CenterEnrolling: 8701 location
RECRUITINGPhase 2NCT06253611

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

This is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and...

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative GroupEnrolling: 12020 locations
RECRUITINGPhase 2NCT06451211

Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer

The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the...

Sponsor: Sun Yat-sen UniversityEnrolling: 531 location
RECRUITINGNCT07175155

Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for...

Hypoxaemia during sedated gastrointestinal endoscopy exceeds 40 % in morbidly obese (BMI ≥ 35 kg m-²) patients. High-flow nasal cannula alone often fails because of persistent...

Sponsor: Zhejiang UniversityEnrolling: 4105 locations
RECRUITINGNCT07067983

Clinical Evaluation of GRAPE Model for Gastric Cancer Screening

A Prospective Study Evaluating the Performance of the GRAPE Model in Gastric Cancer Screening and Its Detection Rates Across Different Disease Stages

Sponsor: Zhejiang Cancer HospitalEnrolling: 10000001 location
RECRUITINGNCT06521541

Whole Course Multi-model Prehabilitation to Improve Clinical Outcome in Patients Undergoing Neoadjuvant Treatment Prior...

The intention of research is to establish a multimodal prehabilitation protocol in patients who undergo neoadjuvant chemotherapy prior to gastrectomy, explore the feasibility and...

Sponsor: The Affiliated Hospital of Qingdao UniversityEnrolling: 901 location
RECRUITINGPhase 2NCT03825861

Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer

Phase II single-arm study designed to evaluate the efficacy and safety of preoperative chemotherapy with FOLFIRINOX regimen. The investigators will include 27 patients with...

Sponsor: Instituto do Cancer do Estado de São PauloEnrolling: 271 location
RECRUITINGNCT07481110

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer. It also aims to...

Sponsor: Société Algérienne de Formation et Recherche en OncologieEnrolling: 100015 locations
RECRUITINGNCT06383793

Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy...

As of now, although the safety of π-shaped anastomosis and the overlap method has been separately discussed in different contexts, there have been few studies considering a direct...

Sponsor: Northern Jiangsu People's HospitalEnrolling: 1001 location
RECRUITINGNCT05412758

Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)

Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The...

Sponsor: Imperial College LondonEnrolling: 6481 location
RECRUITINGPhase 2NCT06487429

Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course...

This study is a prospective, open label, phase II clinical study intended to include patients with locally advanced gastric adenocarcinoma who have not undergone any treatment and...

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling: 281 location
RECRUITINGPhase 1 / Phase 2NCT05438459

GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With...

Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with...

Sponsor: Kyushu UniversityEnrolling: 1301 location
RECRUITINGPhase 1NCT06043466

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 302 locations
RECRUITINGNCT05804331

The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study

To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for...

Sponsor: Western Sydney Local Health DistrictEnrolling: 5001 location
RECRUITINGPhase 1 / Phase 2NCT06298916

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and...

Sponsor: Lantheus Medical ImagingEnrolling: 265 locations
RECRUITINGPhase 1 / Phase 2NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation...

Sponsor: Perspective TherapeuticsEnrolling: 1123 locations
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGPhase 2NCT06503146

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET...

Sponsor: National Cancer Institute (NCI)Enrolling: 3201 location
RECRUITINGPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...

Sponsor: Nurix Therapeutics, Inc.Enrolling: 34517 locations
RECRUITINGNCT07142122

Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the...

This prospective, single-center, randomized, controlled, non-inferiority clinical trial aims to compare the safety and postoperative quality of life of early upper gastric cancer...

Sponsor: Fujian Cancer HospitalEnrolling: 761 location

Showing 50 of 52 trials.Search all Gastric Cancer trials

Frequently Asked Questions

There are currently 52 clinical trials for Gastric Cancer, with 52 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Gastric Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 3 Phase 3 trials for Gastric Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.